Overview
- Editors:
-
-
Zbigniew Petrovich
-
Department of Radiation Oncology, University of Southern California, USC/Norris Cancer Center, Los Angeles, USA
-
Luc Baert
-
Department of Urology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium
-
Luther W. Brady
-
Department of Radiation Oncology and Nuclear Medicine, Allegheny University Hospitals, Center City, Philadelphia, USA
Access this book
Other ways to access
Table of contents (29 chapters)
-
-
-
-
-
- C. M. Bender, P. A. Jones
Pages 37-51
-
- E. C. M. Ooms, R. W. Veldhuizen
Pages 53-62
-
-
- M.-A. D’Hallewin, N. De Graeve, L. Baert
Pages 89-92
-
- W. Ijzerman, P. Jung, G. Jakse
Pages 93-102
-
- M.-A. D’Hallewin, L. Baert
Pages 103-112
-
- M.-A. D’Hallewin, H. Vanherzeele, L. Baert
Pages 113-125
-
- A. P. M. Van Der Meijden, R. Sylvester, C. Bouffioux, R. van Velthoven, K.-H. Kurth, W. Höltl et al.
Pages 127-133
-
- E. C. Skinner, S. D. Boyd, G. Lieskovsky, D. G. Skinner
Pages 135-141
-
-
-
- L. Baert, A.-A. Elgamal, H. Van Poppel
Pages 169-185
-
- H. Van Poppel, M. Van Den Heuvel, Y. Lievens, E. Van Limbergen, L. Vanuytsel, L. Baert
Pages 187-195
-
- W. U. Shipley, A. L. Zietman, D. S. Kaufman, A. F. Althausen, N. M. Heney
Pages 197-204
-
- R. Sauer, S. Birkenhake, R. Kühn, C. Wittekind, P. Martus, J. Dunst et al.
Pages 205-214
-
- L. Vanuytsel, W. Van Den Bogaert
Pages 215-220
About this book
Bladder cancer represents a major challenge to the oncologist. In spite of new tech niques for early diagnosis and innovative imaging procedures for staging, the outcome in terms of cure has not improved during the past ten years. Fortunately, about 74% of the patients present with localized disease, with 18% presenting with localized and regional disease, and 3% with distant metastases at diagnosis. In accordance with the stage at presentation, 94% of patients with localized disease are controlled at 5 years, as are 50% of patients with local and regional disease but un fortunately only 7% of those with distant disease. The survival data for Afro-Americans are more grave, with only 79% of patients with localized disease surviving at 5 years, 38% with local and regional disease, and 4% with disseminated disease. Even after 5 years, however, patients continue to fail not only locally and regionally but also with disseminated disease, thereby creating enigmas as to the continued influence of basic molecular changes, basic etiologic agents, and unsuspected more advanced disease, as well as demonstrating the inadequacies of local surgical treatment programs. These factors have led to braoder programs of combined integrated multimodal treatment earlier in the course of the disease process. Clearly, these newer innovative programs have placed increasing emphasis on the combination of surgery with radiation therapy and chemotherapy.
Editors and Affiliations
-
Department of Radiation Oncology, University of Southern California, USC/Norris Cancer Center, Los Angeles, USA
Zbigniew Petrovich
-
Department of Urology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium
Luc Baert
-
Department of Radiation Oncology and Nuclear Medicine, Allegheny University Hospitals, Center City, Philadelphia, USA
Luther W. Brady